Altimmune (ALT)
(Delayed Data from NSDQ)
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
by Zacks Equity Research
Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
by Zacks Equity Research
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
by Zacks Equity Research
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
by Zacks Equity Research
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
by Zacks Equity Research
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
by Zacks Equity Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio
by Zacks Equity Research
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
by Zacks Equity Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Encompass Health (EHC) to Build New Rehab Unit in Missouri
by Zacks Equity Research
Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.
Teladoc (TDOC) Widens Primary360 Offerings With New Services
by Zacks Equity Research
Teladoc (TDOC) will provide in-home and on-demand phlebotomy services for its Primary360 members with Scarlet Health's support.
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) continues witnessing a rise in the usage of its virtual care services, which is a vital driver.
Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio
by Zacks Equity Research
Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.
Here's Why Select Medical (SEM) Stock is a Strong Buy Now
by Zacks Equity Research
Strategic alliances are bolstering Select Medical's (SEM) growth potential while mitigating the risk factor.
Universal Health (UHS) Cuts Guidance, Falls 6.1%: What's Ahead?
by Zacks Equity Research
Universal Health's (UHS) acute care hospitals experience lower-than-expected patient volumes in the second quarter, inducing a decline in revenues and profits.